HC Wainwright issued their Q1 2025 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on Thursday, ...

Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Shares of Core Scientific Inc. (CORZ) gained almost 8% in Tuesday’s regular session and extended gains during after-hours ...

H.C. Wainwright raised the firm’s price target on ProQR Therapeutics (PRQR) to $12 from $10 and keeps a Buy rating on the shares. The firm says ...

Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on IN8bio (INAB) to $6 from $8 and keeps a Buy rating on the ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision ...

REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema achieved 15.7% weight loss compared to 3.1% with placebo, ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. initiated coverage of Inuvo (NYSEAM:INUV) with a Buy recommendation. As of March 4, 2025, the average one-year price target for Inuvo is ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. initiated coverage of Westwater Resources (NYSEAM:WWR) with a Buy recommendation. What is the Fund Sentiment? There are 59 funds or ...